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I
n primary aldosteronism (PA), autonomous production of the salt-retaining hormone, aldosterone, leads to hypertension and may be associated with hypokalemia (due to the kaliuretic action of aldosterone) (1, 2) . Recent decades have witnessed a marked resurgence in clinical interest in PA and the rate at which this disorder is sought and diagnosed among the hypertensive population. This change has stemmed from the recognition that PA is much more common as a cause of hypertension than previously thought, accounting for possibly 5% to 13% of patients (3) (4) (5) ; only a minority (,25% in most series) of patients with PA present with hypokalemia, the rest masquerading as having so-called essential hypertension (3) (4) (5) ; PA is associated with disproportionately high rates of cardiovascular events and renal damage relative to the degree of hypertension (6) (7) (8) , in keeping with findings from experimental and clinical studies suggesting that aldosterone excess has detrimental effects on the heart, blood vessels, and kidney that are at least partly independent of its effects on blood pressure (9) (10) (11) (12) ; and this excess in cardiovascular and renal morbidity is ameliorated by medical or surgical treatment specifically directed against aldosterone excess (6) , arguing for intensified efforts to make the diagnosis in order for patients to be offered appropriate, optimal management rather than remain on less effective nonspecific antihypertensive therapy.
The diagnostic workup of PA involves three main steps: screening by measurement of the plasma aldosterone/ renin ratio (ARR), which is elevated in PA; confirmatory testing to definitively confirm or exclude the diagnosis; and determining the subtype, including the differentiation [primarily by adrenal venous sampling (AVS)] of unilateral forms of PA, which are potentially curable by unilateral adrenalectomy, from bilateral forms, which are usually treated medically by agents that antagonize aldosterone action, and genetic testing for rare familial forms.
Demonstration of aldosterone production that is relatively autonomous of its normal chronic regulator, angiotensin II, confirms the diagnosis in patients who screen positive for PA by ARR testing. This diagnosis can be accomplished by demonstrating aldosterone production that cannot be suppressed when plasma levels of renin (and hence angiotensin II) have been suppressed for a particular period of time by one of several commonly used special maneuvers (13) . International guidelines recommend one of four tests for this purpose (oral sodium loading, saline infusion, fludrocortisone administration with oral sodium loading, and captopril challenge testing) but have not committed to any one of them as being preferred over the others (14) . Of these, we have found fludrocortisone suppression testing (FST) to be the most reliable (1) , but this test is rarely used elsewhere because it is difficult to perform and expensive, requiring hospital admission for several days.
A widely used alternative to FST is saline suppression testing (SST, involving measurement of the plasma aldosterone response to an intravenous infusion of 2 L of 0.9% normal saline given over a 4-hour period while subjects are maintained in the recumbent position), because it requires only a brief outpatient attendance. However, in our earlier experience, recumbent saline suppression testing (RSST) appeared to lack sensitivity, with many patients with PA, including unilateral forms, being missed (15) . Because aldosterone levels are higher in the upright (e.g., seated) position compared with recumbency in many patients with PA (nearly all with bilateral and up to half with unilateral forms), and upright aldosterone levels are used for diagnosis during FST, we hypothesized and demonstrated in a pilot study (16) that SST is more sensitive when performed on upright than on recumbent patients and that RSST preferentially misses patients with PA in whom aldosterone is responsive to upright posture. In our pilot study, of 24 patients with confirmed PA, 23 tested positive by seated saline suppression testing (SSST) compared with only eight by RSST. Because of the small number of patients examined, however, we were not able to confirm superiority of SSST over RSST in diagnosing PA in the subgroup with unilateral forms, who are especially important to detect because hypertension in those subjects is potentially curable by unilateral adrenalectomy. Furthermore, we were unable to assess specificity of either SSST or RSST because of the inclusion of only very small numbers of patients in whom PA had been excluded by FST.
We herein report results from a substantially expanded patient cohort intended to validate our previous findings, better assess sensitivity (including among patients with the unilateral subtype of PA) and specificity, and determine optimal diagnostic criteria for SSST as a reliable and more convenient alternative to FST in confirmatory testing for PA.
Methods

Subjects
This study was completed at the Endocrine Hypertension Research Centre, Greenslopes and Princess Alexandra Hospitals, Brisbane. The diagnosis of PA and its subtypes was based on the center's strict protocol (17) . The institutional ethics committee approved the study. Patients were informed of the objectives of the study, and written informed consent was obtained in all cases.
Of 402 patients who underwent FST between April 2012 and June 2017, 100 agreed to participate in and completed the study (Fig. 1 ). Of these, FST was performed in 86 patients who were hypertensive with elevated ARR to definitively confirm or exclude PA and in the remaining 14 to determine whether PA had been cured from a biochemical perspective after unilateral adrenalectomy. In all, 108 studies were included in the analysis because eight patients underwent testing both before and after adrenalectomy.
Confirmation of the diagnosis of PA
The study cohort included patients who were hypertensive with a plasma ARR .70 (plasma aldosterone concentration expressed in picomoles per liter, plasma active renin concentration in milliunits per liter) when plasma aldosterone was measured by RIA or .55 when measured by highperformance liquid chromatography tandem mass spectrometry [HPLC-MS/MS using a method previously developed in our laboratory (18) ] on at least two occasions, and who had accepted our recommendation to undergo FST to definitely confirm or exclude PA and agreed to also undergo SST on two occasions, once supine and once seated. In addition, patients who had undergone unilateral adrenalectomy as surgical treatment of PA and had completed postoperative FST to determine whether PA had been cured from a biochemical perspective were invited to participate.
Patients undergoing FST were admitted to the hospital to ensure adherence to the dietary and posture requirements of the test protocol and to facilitate monitoring of plasma potassium levels and other parameters. Blood was collected in the morning after $2 hours of upright posture, for measurement of ARR after hypokalemia had been corrected with potassium supplements and while patients were being encouraged to maintain a liberal dietary salt intake. Before testing, diuretics (including spironolactone, eplerenone, and amiloride) were always ceased for $4 weeks, and, wherever possible (which was in most patients), beta-blockers, dihydropyridine-type calcium channel antagonists, angiotensin-converting enzyme inhibitors, and angiotensin II receptor antagonists were ceased for $2 weeks and withheld throughout the subsequent diagnostic steps. Where necessary, control of hypertension was maintained by substituting these agents with others (including verapamil slowrelease plus or minus hydralazine, prazosin, and moxonidine) which have a lesser effect on aldosterone and renin levels (15, 17) . The diagnosis of PA was based on FST criteria (17) and was confirmed when plasma aldosterone concentration, measured by HPLC-MS/MS in blood collected at 1000 hours in seated patients after at least 2 hours upright (sitting, standing, or walking), failed to suppress to ,133 pmol/L (adjusted after in-house validation from the previously used cutoff of 165 pmol/L when measured by RIA) at the conclusion of 4 days' administration of a high-sodium diet and slow-release sodium chloride (slow Na, 30 mmol three times daily with meals) and of fludrocortisone acetate (0.1 mg every 6 hours), provided that on day 4, upright plasma direct renin concentration (DRC) was suppressed to ,8.4 mU/L, facilitated by maintaining a salt intake of $3 mmole/kg/d of sodium (confirmed by measuring urinary sodium excretion during the last 24 hours of the FST) and by having the patient see a dietician within 24 hours of admission; plasma potassium was within the normal range, thereby avoiding the possibility of a missed diagnosis due to hypokalemia-induced suppression of aldosterone release, or conversely a false positive FST due to stimulation of aldosterone by hyperkalemia from overreplacement; and plasma cortisol concentration was lower at 1000 hours (seated or standing) than at 0700 hours (recumbent overnight), excluding an acute increase in corticotropin, which could prevent aldosterone suppression. Thus, if plasma DRC was $8.4 mU/L or plasma cortisol rose or if plasma potassium was raised on day 4, an otherwise positive result would be labeled "inconclusive," and if plasma potassium was subnormal on day 4, an otherwise negative result would also be labeled "inconclusive." Furthermore, if AVS was performed despite an inconclusive FST, and this demonstrated lateralization of aldosterone production to only one adrenal, such patients would be included in the group labeled as confirmed PA. Adherence to these diagnostic criteria for "positive," "negative," and "inconclusive" FST was intentionally strict to maximize confidence of a correct diagnosis and thereby facilitate reliability of analysis of the diagnostic performance of SSST and RSST. Therefore, even if upright DRC on day 4 was only slightly (e.g., ,5%) higher than 8.4 mU/L or plasma cortisol on day 4 was only slightly higher at 1000 hours than at 0700 hours, an otherwise positive test (based on an upright plasma aldosterone at 1000 hours on day 4 of $133 pmol/L) was labeled "inconclusive."
Subtype differentiation
In all patients with hypertension and elevated ARR undergoing FST to definitively confirm or exclude PA, glucocorticoidremediable familial PA was excluded by testing (18) for the hybrid 11b-hydroxylase/aldosterone synthase gene. All patients with positive FST and most with FST results that were inconclusive but suggestive of PA underwent adrenal CT scanning performed with fine (2.5 to 3.0 mm) slices and, regardless of the CT findings, were offered AVS to differentiate unilateral from bilateral adrenal aldosterone production. Other forms of secondary hypertension were excluded on the basis of normal 24-hour urinary catecholamines and metanephrines, plasma free metanephrine, renal artery duplex ultrasound, isotopic renography, and overnight 1 mg dexamethasone suppression testing.
Diagnostic criteria for AVS
Before March 2015, AVS was performed without ACTH stimulation. From March 2015, AVS was performed while patients were receiving an intravenous infusion of ACTH (250 mg in 250 mL normal saline, infused at a rate of 50 mL/h), commencing $30 minutes before commencement of AVS. At least threefold gradients between adrenal and peripheral venous cortisol concentrations for non-ACTH-stimulated AVS, and fivefold for ACTH-stimulated AVS, were taken to indicate adequate sampling from adrenal veins. If the aldosterone/ cortisol ratio (averaged if two or more samples) on one side was at least twice the simultaneous peripheral venous ratio, and on the other side there was a ratio the same as or less than the peripheral ("contralateral suppression"), the study was considered to have demonstrated lateralization of aldosterone production. Patients demonstrating adrenal venous aldosterone/ cortisol ratios that were higher than peripheral on both sides were considered to have aldosterone overproduction that was bilateral, consistent with bilateral adrenal hyperplasia.
SST protocols
Patients who completed FST also underwent SST (aldosterone concentration measured basally at 0800 hours and at completion of an infusion of 2 L normal saline over 4 hours), both recumbent (RSST; infusion commenced 30 minutes after assuming recumbency) and seated (SSST; infusion commenced 30 minutes after assuming the seated position), with the two SSTs conducted $2 weeks apart and in randomized order. For the SSST and RSST, the cutoffs for normal suppression of plasma aldosterone were derived from the combined consideration of receiver operating characteristic (ROC) analysis and assessment of the diagnostic performance of a range of cutoffs around the ROC-predicted value. For both forms of SST, failure of plasma aldosterone to suppress to below the defined cutoff levels was considered diagnostic for PA provided that DRC at 4 hours was ,8.4 mU/L and plasma cortisol concentration was lower at 4 hours than basally (0 hours).
Determining aldosterone responsiveness to upright posture
Aldosterone responsiveness to upright posture was determined by measuring plasma aldosterone levels at 0700 hours after overnight recumbency and again at 1000 hours after 3 hours of upright posture. Patients were classified as postureresponsive if upright plasma aldosterone levels were $50% higher than recumbent or unresponsive if upright levels were ,50% higher, or lower, than recumbent levels.
Measurement of plasma aldosterone and renin concentrations
Plasma DRC was determined by direct renin assay, which uses chemiluminescent immunoassay technology (DiaSorin, Liaison, Italy). The interassay coefficient of variation was 7.4% at 26 mU/L and 6.0% at 106 mU/L. The intra-assay coefficients of variation at 15, 33, 82, and 258 mU/L were 3.7%, 2.8%, 2.0%, and 1.2%, respectively. The assay working range was #500 mU/L. For FST, RSST, and SSST, plasma aldosterone was measured by HPLC-MS/MS, with a method recently validated in our laboratory (18) . The interassay coefficient of variation was 9.3% at 242 pmol/L and 6.0% at 1321 pmol/L. The intra-assay coefficient of variation was 7.3% at 238 pmol/L and 4.3% at 1344 pmol/L.
Statistical analysis
The data were analyzed in SPSS 24 for Windows (SPSS, Chicago, IL). All values are expressed as median and range unless otherwise specified. Pairwise comparisons were performed with a Wilcoxon test for dependent samples and MannWhitney test for independent samples. Statistical significance was accepted when the two-tailed P value was ,0.05. MedCalc 15 (MedCalc Software, Ostend, Belgium) was used to compare the differences in the areas under the ROC curve. McNemar test was used to compare sensitivity and specificity.
Results
Results of FST and AVS
Among the 108 studies, FST confirmed PA in 73, excluded PA in 18, and was inconclusive in 17 patients (Fig. 1) . Of the patients with inconclusive FST, four were subsequently confirmed as having a unilateral form of PA after lateralization of aldosterone production to one adrenal on AVS, making a total of 77 with confirmed PA. Of these, 28 had unilateral PA, 40 had bilateral PA, eight have not yet undergone AVS, or their AVS results were inconclusive (and hence their PA subtype remains undetermined), and one had residual PA after unilateral adrenalectomy. Clinical and biochemical characteristics of the patient cohort subgrouped according to final diagnosis are shown in Table 1 .
In all 17 inconclusive FSTs, upright plasma aldosterone at 1000 hours on day 4 was $133 pmol/L (consistent with a positive test), but the test was categorized as inconclusive either because day 4 upright DRC was $8.4 mU/L (n = 4) or day 4 plasma cortisol was higher at 1000 hours than at 0700 hours (n = 9), or both (n = 4).
Of the 28 patients who lateralized on AVS, 22 underwent unilateral adrenalectomy. In keeping with a correct diagnosis of unilateral PA, with regard to hypertension, 17 were cured (blood pressure #140/90 mm Hg off all antihypertensive medications), and the remaining five improved (similar blood pressure with less antihypertensive medication, or a reduction in blood pressure with either the same amount or less antihypertensive medication), consistent with complete or partial clinical success, respectively, according to the Primary Aldosteronism Surgical Outcomes criteria (19) . Hypokalemia was corrected where present in all patients, and the ARR returned to normal (thus meeting the Primary Aldosteronism Surgical Outcomes criteria for complete biochemical success) in all but two patients ( Table 2) . Of the 13 patients who underwent postoperative FST, 11 met the biochemical criteria for cure of PA, and the remaining two showed improvement, with marked lowering in (but incomplete suppression of) day 4 upright aldosterone levels.
Results of SSST and RSST: ROC analyses
ROC analysis was undertaken to compare the diagnostic performances of SSST and RSST by comparing the areas under the ROC curves Before ROC analysis, all patients with inconclusive FST (other than two who lateralized on AVS and had conclusive SSST and RSST results; n = 15 excluded) and all with inconclusive SSST (n = 3) or RSST (n = 9) were excluded, leaving a cohort of 87 patients (70 with and 17 without PA as defined by FST results in 85 patients or lateralization on AVS in 2 with inconclusive FST; Fig. 2 ). For both SSST and RSST, the area under the curve (AUC) was significantly (P , 0.001) greater than that under the reference line (AUC = 0.5), but the AUC for SSST was significantly greater than that for RSST (0.959 6 0.022 vs. 0.796 6 0.056; P , 0.01) (Fig. 3) .
According to ROC analysis, the predicted optimal plasma aldosterone cutoff for SSST as defined by the highest Youden index (YI) was found to be 161 pmol/L (sensitivity 88.6%, specificity 94.1%; YI = 0.827) with a clear-cut single peak in YI at this level. To select a cutoff with optimal clinical relevance, we reasoned that confirmatory testing should have high specificity for PA (thereby reliably identifying patients who do not have PA who can then be spared from undergoing AVS, an invasive and costly procedure that is not without risk) but high sensitivity especially for unilateral forms of PA (which are potentially curable by unilateral adrenalectomy). Applying these considerations, we found that a cutoff of $162 pmol/L was optimal, correctly ruling out PA in 16 (94.1%) of 17 patients in whom PA was excluded by negative FST and correctly identifying PA in 24 (96.0%) of 25 patients with PA who lateralized on AVS. Therefore, in this study we chose $162 pmol/L as the plasma aldosterone cutoff for SSST.
For RSST, the peak YI, which occurred at a plasma aldosterone of 75.5 pmol/L, was much lower than that for SSST (sensitivity 58.6%, specificity 88.2%; YI = 0.468), predominantly because of poorer sensitivity, even at this low cutoff level. Furthermore, unlike for SSST, the peak YI for RSST was not clear-cut, with secondary peaks occurring at cutoff plasma aldosterone levels of 56 (YI = 0.434), 67.5 (YI = 0.452), and 105.5 (YI = 0.400) pmol/L. The YI was therefore of limited usefulness in According to the McNemar test, the difference in sensitivity between the two tests was statistically significant (P , 0.001), but the difference in specificity was not (P = 1.00).
Results of SSST and RSST: performance among entire cohort and according to PA subtype Returning to the entire 108 studies performed, of the 77 patients with confirmed PA (28 unilateral, 40 bilateral, 8 of undetermined subtype, and 1 residual PA after unilateral adrenalectomy), 67 (87.0%) tested positive by SSST and only 29 (37.7%; P , 0.001 vs. SSST) tested positive by RSST (Table 3) . Of the 28 with unilateral PA, SSST tested positive in 26 (92.8%), negative in one (3.6%), and inconclusive in one (3.6%), whereas RSST tested positive in 19 (67.9%; P , 0.05 vs. SSST), negative in seven (25.0%), and inconclusive in two (7.1%). Of the 40 with bilateral PA, SSST was positive in 34 (85.0%), negative in five (12.5%), and inconclusive in one (2.5%), whereas RSST was positive in only eight (20.0%; P , 0.001 vs. SSST), negative in 29 (72.5%), and inconclusive in three (7.5%). Of the 18 patients in whom PA was excluded by FST, SSST was negative in 17 (94.4%) and positive in one (5.6%), whereas RSST was negative in 17 (94.4%) and inconclusive in one (5.6%).
Positive and negative likelihood ratios were 15.5 and 0.14, respectively, for SSST and 6.7 and 0.66, respectively, for RSST.
Three (2.8%) of the 108 SSSTs were designated "inconclusive" despite meeting the criterion for a positive study (plasma aldosterone at 4 hours $162 pmol/L), either because DRC at 4 hours was $8.4 mU/L (n = 1) or plasma cortisol was higher at 4 hours than basally (n = 2). The proportion of SSSTs that were inconclusive was significantly less than that for FSTs (15.7%; P , 0.01). In all nine (8.3%; P = 0.07 vs. SSST; P = 0.09 vs. FST) of the 108 RSSTs that were designated inconclusive, plasma aldosterone was again above the cutoff for normal suppression ($106 pmol/L), but plasma cortisol was higher at 4 hours than basally.
Relationship of SSST and RSST results to posture responsiveness
Of the 77 patients for whom a diagnosis of PA was confirmed by positive FST (or lateralization on AVS), 30 were posture-unresponsive in terms of aldosterone production and 47 were posture-responsive. SSST was positive in 27 (90.0%) posture-unresponsive and in 40 (85.1%) posture-responsive subjects. By contrast, RSST was positive in 18 (60.0%, P , 0.01 vs. SSST) of the posture-unresponsive and only 11 (22.9%, P , 0.001 vs. SSST) posture-responsive subjects.
Of the 28 patients with unilateral PA, 18 (64.3%) were posture unresponsive and 10 (35.7%) posture responsive. Of these, SSST was positive in 17 (94.4%) posture-unresponsive and nine (90.0%) postureresponsive patients, whereas RSST was positive in 16 (88.9%, NS vs. SSST) posture-unresponsive and only three (30.0%, P , 0.01 vs. SSST) posture-responsive patients.
Of the 40 patients with bilateral PA, nine (22.5%) were posture-unresponsive and 31 (77.5%) postureresponsive. Of these, SSST was positive in seven (77.8%) patients who were posture-unresponsive and 27 (87.1%) patients who were posture-responsive, whereas RSST was positive in only one (11.1%, P , 0.01 vs. SSST) patient who was posture-unresponsive and only seven (22.6%, P , 0.001 vs. SSST) patients who were postureresponsive.
There were no differences between patients who were posture-unresponsive and patients who were responsive in the proportion of SSSTs that were positive, either within the total PA cohort or in the unilateral and bilateral subgroups. By contrast, RSST was positive in a greater proportion of patients who were posture-unresponsive vs. patients who were responsive among the total PA cohort (P , 0.01) and in those with unilateral PA (P , 0.01) but not in those with bilateral PA.
Comparison of basal recumbent and upright aldosterone levels according to posture responsiveness and lateralization status
As shown in Table 4 , whereas recumbent plasma aldosterone levels on the basal day of FST were higher in those with posture-unresponsive vs. responsive PA (P , 0.001) and in those with unilateral vs. bilateral PA (P , 0.001), upright levels were similar among all four PA subgroups.
Basal aldosterone levels for SSST (patients upright) were significantly higher than basal levels for RSST (patients recumbent) for the combined PA cohort (P , 0.01), the posture-responsive subgroup (P , 0.05), and the bilateral subgroup (P , 0.001) but not for the posture-unresponsive or unilateral subgroups (Fig. 4) . 
Discussion
The results of the current, expanded validation study confirm findings of our previous preliminary report (16) in showing that SSST is superior to RSST in correctly confirming the diagnosis of PA, especially in patients with posture-responsive and bilateral forms, with a low rate of false negatives, almost all of them with bilateral PA. The recruitment of larger numbers of patients than in our previous study allowed us to derive a firm cutoff plasma aldosterone value for the SSST by using ROC analysis; observe superiority of SSST over RSST in confirming PA in patients with unilateral surgically correctable forms (again, especially if posture responsive), in whom it is particularly important that the diagnosis is not missed; and demonstrate high specificity for SSST with a low rate of false positives among patients without PA. SSST is therefore a reliable alternative to FST, which is much more complicated and expensive. Furthermore, when strict diagnostic criteria are applied for all three tests, SSST appears to be associated with fewer inconclusive results than FST or RSST.
Recognizing the possibility of false positive ARR results during screening for PA, current guidelines recommend that patients with positive ARR levels undergo confirmatory testing for PA before undergoing further diagnostic workup (including AVS) to determine the subtype (14) . Those who test negative (PA excluded) can then be spared from having to undergo AVS, which is expensive, invasive, and technically difficult. It is therefore particularly important that a confirmatory test for PA have high specificity to minimize the number of patients without PA who demonstrate false positive results and are therefore inappropriately subjected to AVS. It could also be argued that another major prerequisite of confirmatory testing is to have high sensitivity, especially for unilateral PA, given that the primary purpose of AVS is to identify subjects with unilateral forms who are candidates for potentially curative unilateral adrenalectomy and to lateralize the side of adrenal aldosterone production preoperatively. With these considerations in mind, our intent was to set the SSST cutoff level at a point that was low enough to optimize detection of unilateral PA, but high enough to ensure minimal occurrence of false positives (accepting that this cutoff would mean missing a few patients with bilateral PA). The final cutoff level that we chose ($162 pmol/L) was associated with only one (4%) false negative SSST among 28 patients with unilateral PA and only one (6%) false positive among 18 without PA. The number of false negatives among 40 patients with bilateral PA was still modest at five (13%), and we believe this number is acceptable, especially when we take into account that a negative result in such patients would not preclude them from undergoing a trial of medical treatment of PA.
Although the FST has been the favored approach to confirmatory testing at our center for the last four decades, few other centers have adopted its use, primarily because of the complex protocol and long (5-day) duration of the study. Although adding to the expense, admission to hospital for the duration of the FST facilitates control of posture, diet, and careful monitoring of blood pressure and plasma potassium levels, the latter of which can then be held within the normal range by appropriate doses of slow-release KCl supplementation adjusted daily as needed. Many centers have favored the RSST over FST as an approach to diagnosis because it requires a visit of only several hours and can be conducted on an outpatient basis. However, the results of the current study suggest that it lacks sensitivity for PA, including for unilateral forms. The area under the ROC curve for the RSST was significantly lower than that for the SSST, and there was no clear optimal RSST cutoff plasma aldosterone level based on assessment of ROC YI values, necessitating greater reliance on the clinical considerations outlined here to enable selection of a cutoff level ($106 pmol/L) for use in this study. At this level, although specificity was excellent (94%), sensitivity was low, with false negative studies encountered in 29 (73%) of 40 with bilateral PA and seven (25%) of 28 with unilateral PA. Dropping the cutoff to that with the highest YI ($76 pmol/L) would have resulted in a reduction in specificity to 83% and with five (18%) patients with unilateral PA still demonstrating false negative RSST results. The tendency for RSST to miss posture-responsive PA may help to account for higher percentages of unilateral PA and lower percentages of bilateral forms of PA in some reported series [e.g., in one study, 50% unilateral and 50% bilateral (20) ]. This tendency may also explain why angiotensin-responsive, posture-responsive aldosteroneproducing adenomas have previously been reported by some investigators to be rare. In the current study, 10 (36%) of 28 patients with unilateral PA demonstrated posture responsiveness, and seven (70%) of these cases were missed by RSST. Biglieri et al. (21) , who used RSST to identify PA, reported only four of 98 aldosteroneproducing adenomas to demonstrate responsiveness of plasma aldosterone levels to upright posture.
The occurrence of inconclusive test results in the current study merits further discussion. For all tests that were deemed inconclusive, plasma aldosterone was higher than the diagnostic cutoff level at the end of the test (in keeping with PA), but this was in the presence of inadequate suppression of the renin-angiotensin II system (as defined by a DRC level above a predefined arbitrary cutoff level of 8.4 mU/L) or a rise in ACTH (indicated by a rise in cortisol) in the hours leading up to the final sample collection, either of which might have prevented aldosterone from suppressing normally despite a patient not having PA. Although the proportion of FSTs that were deemed inconclusive seems high at 15.7%, this finding reflected our deliberate intent to apply the diagnostic criteria strictly, given that the FST was chosen as the gold standard against which SSST and RSST were to be assessed. Therefore, even if final DRC levels were only slightly above 8.4 mU/L, or if there was only a slight rise in cortisol leading up to the test's conclusion, for the specific purposes of this study the FST would be considered inconclusive regardless of how high the final plasma aldosterone level was above its diagnostic cutoff. Importantly, despite applying similarly strict criteria, the SSST appeared to be associated with only a very low rate (2.8%) of inconclusive results compared with FST or RSST (8.3%). This finding may reflect a lower degree of stress (and hence a lower likelihood of ACTH rising) in patients undergoing SSST resulting from the short duration of the test compared with FST, and their freedom to comfortably read, watch television, or mobilize to the toilet if necessary compared with RSST. A rise in cortisol (encountered in 13 of the 17 inconclusive FSTs) was the most common reason for FSTs to be deemed inconclusive and accounted for all nine inconclusive RSSTs but only two inconclusive SSSTs. Indeed, a common comment made by participating patients was the greater tolerability of SSST compared with RSST. Previous studies that assessed the diagnostic performance of the RSST have been limited by the use of high ARR cutoff values (thereby selecting patients with more severe forms of PA who are less likely to be missed by RSST) (22, 23) or have reported only modest sensitivity and specificity (24). Rossi et al. (25) , using ROC analysis among 317 patients who underwent RSST to determine an optimal postinfusion plasma aldosterone cutoff value (at 187 pmol/L, measured by radioimmunoassay), reported a sensitivity of 83% but a specificity of only 75% for diagnosis of PA. In a multicenter study reported by Mulatero et al. (23) involving 98 patients who were hypertensive who had screened positive for PA by ARR testing, RSST (with an aldosterone cutoff value of 139 pmol/L, again measured by radioimmunoassay) was positive in 60 (90%) of 67 patients confirmed as having PA by FST and negative in 26 (84%) of 31 with negative FST. However, the cutoff ARR value that they used was high (.40 ng/dL per ng/mL/h, which is approximately twice that used in the current study) and would have led to selection of more severe forms of PA, with a lower likelihood of false negative RSST.
Strengths of the current study include its prospective nature, large size, inclusion of patients with milder forms of PA than in most other studies that have assessed SST or FST, careful approach to screening by ARR testing off interfering medications wherever possible, use of carefully performed inpatient FST as a comparator, measurement of plasma aldosterone responsiveness to upright posture, use of AVS in each case of PA to differentiate unilateral from bilateral forms, randomization of the two forms of SST, and use of HPLC-MS/MS to measure plasma aldosterone.
There were a number of limitations associated with this study. First, selection of patients who were hypertensive for FST was based primarily (and in accordance with international guidelines) on the demonstration of an elevated ARR, the sensitivity of which is likely to have been imperfect despite the measures that were taken to avoid or control for confounding factors (e.g., interfering medications). Therefore, it is possible that a small number of patients with PA evaluated at our center might have been missed. Although it could be argued that a more comprehensive approach to comparing the various forms of suppression testing would have been to include all patients with hypertension, doing so would have been impractical given that FST requires a 5-day inpatient stay and certainly would be contrary to international guidelines for the detection and diagnostic workup of PA. Second, although attempts were consistently made to achieve normokalemia before both FST and SST, this was not always successful, and the short duration of SST made it difficult to do so after commencement of the study. It is therefore possible that failure to correct hypokalemia was the basis for some of the false negative SSTs. Although this is a limitation of both forms of SST, the fact remains that SSST was much more sensitive for detecting PA than RSST. Third, unlike unilateral PA, AVS cannot distinguish bilateral PA from other forms of hypertension. It could therefore be argued that the gold standard used for diagnosing bilateral PA in this study (positive FST) was less robust than that for unilateral PA (positive FST plus lateralization on AVS). Fourth, because HPLC-MS/MS was used to measure plasma aldosterone, the cutoff levels used in the current study for the FST, SSST, and RSST cannot be generalized to institutions that use immunoassay approaches (which tend to give higher values, at least in part because of reduced specificity compared with mass spectrometry). Fifth, although the study was adequately powered to compare sensitivity of RSST and SSST, this assessment is less certain for specificity because only 18 FST-negative, non-PA subjects were available for analysis. Finally, we did not attempt to administer dexamethasone before the last day of FST [as has been previously recommended to overcome the potential confounding influence of rises in ACTH (26) ] or before SST, and this approach may be worthy of evaluation in future studies aimed at further improving the diagnostic performance of SSST.
In conclusion, in this study, compared with the traditional RSST protocol, SSST showed superior sensitivity and similar specificity in confirming PA, particularly for posture-responsive forms and including for unilateral, surgically correctable forms, and it appeared to be well tolerated. Compared with FST, SSST was much simpler and quicker to perform, did not require hospital admission, showed comparable reliability and less often produced inconclusive results, and therefore appears to be an acceptable, less expensive, and less complicated alternative.
